CURRICULUM VITAE - _________________(name)



CURRICULUM VITAE

Amber L. Beitelshees, PharmD, MPH

Assistant Professor, Department of Medicine

University of Maryland School of Medicine

Date April 5, 2019

Contact Information

University of Maryland School of Medicine

Endocrinology, Diabetes and Nutrition Division

670 West Baltimore St, Room 4172

Baltimore, MD 21201

(410) 706-0118

(410) 706-4060 FAX

abeitels@som.umaryland.edu

Education

1994-2001 Doctor of Pharmacy

University of Florida, Gainesville, FL

May 5, 2001

Post Graduate Education and Training

2001-2002 University of Illinois at Chicago

ASHP-accredited Pharmacy Practice Residency

Frank Paloucek, PharmD, ABAT, Director

2002-2005 University of Florida

Cardiovascular Pharmacogenomics Fellowship

Julie A. Johnson, PharmD, Mentor

2003-2005 Master of Public Health (Epidemiology track),

Summa Cum Laude. University of Florida College of Public Health and Health Professions, Gainesville, FL. Funded by the NIH Clinical Research Curriculum Award (K30)

Graduated April 28, 2005.

Medical Licensures

2001 Licensed Pharmacist, Illinois, Active

2001 Licensed Pharmacist, Florida, Active

2015 Licensed Pharmacist, Maryland, Active

Employment History

Academic Appointments

2005- 2007 Research Assistant Professor of Medicine, Washington University, Cardiovascular Division, St. Louis, MO

2007 – 2008 Assistant Professor, University of Florida, College of Pharmacy, Department of Pharmacy Practice, Gainesville, FL

2008-present Assistant Professor of Medicine, University of Maryland School of Medicine, Division of Endocrinology, Diabetes and Nutrition

Other Employment

2007-2008 Hospital Pharmacist, North Florida/South Georgia VA Medical Center, Gainesville, FL

Professional Society Memberships

2000-2002 Member, American Society of Health-System Pharmacists

2001 – present Member, American College of Clinical Pharmacy

2002 – present Member. American Society of Clinical Pharmacology and Therapeutics

Molecular Pharmacology and Pharmacogenetics Section member

2002 – present Member, American Heart Association, Council on Genomic and Precision Medicine

2013 – present Member, American Diabetes Association

Honors and Awards

2002 Richard Hutchinson Award, Resident of the Year, University of Illinois at Chicago

2003 Best Poster, Post-Doctoral Fellow Division, 16th Annual Research Showcase and Awards Day, University of Florida

2003 Finalist, Best Student, Resident, Fellow Paper Award, American College of Clinical Pharmacy 2003 Annual Meeting

2004 Runner-up, Best Student, Resident, Fellow Paper Award , American College of Clinical Pharmacy 2004 Annual Meeting

2005 Kenneth F. Finger Award, Research Fellow of the Year, University of Florida

2009 American Society of Clinical Pharmacology and Therapeutics Presidential Trainee Award; Awarded to my trainee, William F. Robertson, 3rd year pharmacy student.

2009 American College of Clinical Pharmacy Cardiology Practice and Research Network Junior Investigator Award in recognition of outstanding early career research in the area of cardiovascular pharmacotherapy

2010 Delta Omega, Beta Upsilon Chapter, Honorary Society in Public Health

2011 Outstanding Young Alumnus Award, University of Florida

2012 Fellow, American Heart Association

2016 Fellow, American College of Clinical Pharmacy

2019 Sternfels Prize for Drug Safety Discoveries

Administrative Service

Institutional Service

2007 Genomic Medicine Curriculum Working Group, Washington University, St. Louis, MO

2008 Faculty Search Committee, University of Florida, Gainesville, FL

2008 Judge, University of Florida College of Pharmacy Annual Research Day, Gainesville, FL

2010-2016 Chair, Program in Genetics and Genomics Seminar Series, University of Maryland2010-present Member, Research Subcommittee, Division of Endocrinology Diabetes and Nutrition, University of Maryland2012-2015 Member, University of Maryland Faculty Senate

2013-present Member (Chair since 2016), Pharmacogenomics Subcommittee of the P&T Committee

2016-present Alternate member, University of Maryland School of Medicine Council

National Service

2001 – present Ad Hoc reviewer; Annals of Pharmacotherapy (1x/year)

2003 Pharmacology reviewer; ACC/ESC Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy

2005 – present Ad Hoc reviewer, American Journal of Health System Pharmacy (1x/year)

2006 – present Ad Hoc reviewer, Current Opinion in Molecular Therapeutics (0.5x/year)

2006 – present Ad Hoc reviewer, Expert Opinion on Pharmacotherapy (0.5/year)

2006, 2010 Abstract reviewer, American Society of Clinical Pharmacology and Therapeutics Annual Meeting

2007 – present Ad Hoc reviewer, American Journal of Cardiology (1x/year)

2007 – 2009 Grant Reviewer: American Heart Association, National Center

2008 – present Ad Hoc reviewer, Circulation (1x/year)

2008 – present Abstract reviewer, American Heart Association Scientific Sessions

2009 – present Ad Hoc reviewer, Diabetes (1x/year)

2009 – present Ad Hoc reviewer, Circulation: Cardiovascular Genetics (2x/year)

2009 Ad Hoc reviewer, VA Cardiology Merit Review Subcommittee

2010 – present Review Editorial Board of Frontiers in Pharmacogenetics

2010 – present Ad Hoc reviewer, Pharmacogenomics (1x/year)

2011 – present Ad Hoc reviewer, Lancet (1x/year)

2011– present Member on the Program Committee of the Functional Genomics & Translational

Biology Council for the American Heart Association Scientific Sessions

2011– 2013 Member on the AHA writing group for Pharmacotherapy in Chronic Kidney

Disease Patients Presenting with Acute Coronary Syndrome

2012 – present Ad Hoc reviewer, Clinical Pharmacology & Therapeutics (2x/year)

2012– present Ad Hoc reviewer, Journal of the American Medical Association (1x/year)

2015 Abstract reviewer, American Society of Human Genetics Annual Meeting

2016 Grant Reviewer: NIH Special Emphasis Panel for CSR (ZRG1)

2018 Grant Reviewer NIH ZRG1, Societal and Ethical Issues in Research (SEIR-B)

Teaching Service

2002-2003 Supervisor

Practicum I, PHA 5941, University of Florida,

3 hours of supervision to 1st year pharmacy students in community outreach sites (15 students).

2003-2005 Lecturer

Pharmacotherapy I, PHA 5781, University of Florida, 1st year pharmacy students (125 students)

Introduction to cardiovascular disease, 2 hour lecture.

2003-2004 Lecturer

Pharmacotherapy II, PHA 5782, University of Florida, 2nd year pharmacy students (125 students)

Arrhythmias,4 hour lecture, Fall 2004.

Chronic stable angina, 2 hour lecture, Fall 2003.

2002-2004 Lecturer

Pharmacological Basis of Therapeutics I, PHA 5516, University of Florida, 2nd year pharmacy students (125 students)

Calcium channel blockers, 1.5 hour lecture, Fall 2003-2004.

Antihyperlipidemics, 1.5 hour lecture, Fall 2002-2004.

Anticoagulants, 1.5 hour lecture, Fall 2002.

2005-2007 Lecturer

Computational Statistics Genetics, M21-621, Washington University, Genetic Epidemiology Masters Students (30 students)

Pharmacodynamic pharmacogenetics  1.5 hour lecture, Fall 2005 and Spring 2007

Leveraging informatic tools to conduct pharmacogenetics research, 1.5 hour lecture, Fall 2005 and Spring 2007.

Introduction to Pharmacogenomics, 1.5 hour lecture, Spring 2007.

2006 Lecturer

Introduction to Clinical Translational Research, Washington University, sub-specialty research fellows and junior faculty (20 students)

Integration of genomic information into therapy selection, 1.5 hour lecture, Spring 2006.

2006 Lecturer

Principles of Pharmacology, Washington University M70, 2nd year medical students (130 students)

Pharmacogenomics I & II, 2 hour lecture, Fall 2006.

2007-2008 Lecturer and Case Discussion Leader

Pharmacotherapy II PHA5782, University of Florida, 2nd year pharmacy students (125 students)

Chronic Heart Failure, 4 hours of lecture and 1 hour case, Fall 2007-2008.

2008 Lecturer

Pharmacogenomics PHA 6449, University of Florida, 1st and 2nd year graduate students (20 students), 5 hours of lecture, Spring 2008.

2009-2011 Small Group Discussion Leader

Host Defenses & Infectious Diseases (HDID), MSPR 520, University of Maryland medical students (20 students)

Pharmacogenomics, 1 hour small group discussion Fall 2009-2011.

2009-2017 Lecturer

Pharmacogenomics, PHMY 532, University of Maryland School of Pharmacy (30 students), Hypertension Pharmacogenetics, 2 hours lecture Fall 2009, 2010, 2012-2017.

2009-2011 Lecturer

Genetic Epidemiology, PREV 711, University of Maryland, graduate students (20 students) Pharmacogenetics, 1.5 hour lecture Spring 2009-2011.

2009-2017 Lecturer

Human Genetics, HGEN 601, University of Maryland, graduate students (15-20 students)

Human Genome-Genetic Variation, 1 ½ hour lecture and Pharmacogenomics & Personalized Medicine, 1.5 hour lecture. Fall 2009-2017.

2010. Lecturer

Host Defenses & Infectious Diseases (HDID), MSPR 520, University of Maryland medical students (130 students)

Pharmacogenomics, 1 hour lecture Fall 2010.

2011 Lecturer

Applied Bioinformatics, GPLS 716, University of Maryland graduate students (30 students) Human Genome & SNPs, 2 hour lecture and hands-on software exercises. Spring 2011.

2012-2015 Lecturer

Colloquium of Science for the OSR Summer Research Training Programs, University of Maryland (50 students)

A Personal Journey toward Personalized Medicine. June 2012-2015

2012-2018 Lecturer

Foundations of Disease, MSPR 523, University of Maryland medical students (130 students) Pharmacogenomics, 1 hour lecture Fall 2012-2014 and Fall 2016-2018

2012-2018 Small Group Discussion Leader

Foundations of Disease, MSPR 523, University of Maryland medical students (20 students) Pharmacogenomics, 4 hour small group discussion, Fall 2012-2014 and Fall 2016-2018

2012-2018 Lecturer

Core Course, GPLS 601, University of Maryland graduate students (50 students)

Pharmacogenomics, 1 hour lecture Fall 2012-2018

2013-2019 Lecturer

Principles of Pharmacology, GPLS 607, University of Maryland graduate students (15-20 students) Genome-wide association studies, pharmacogenomics. 1.5 hour lecture Spring 2012-2019

2013-2019 Small Group Discussion Leader

Principles of Pharmacology, GPLS 607, University of Maryland graduate students (15-20 students) Pharmacogenomics case-study. 1.5 hour small group. Spring 2012-2019

2015-2019 Lecturer

Role of Personal Genomes in Medicine, MEDC540, University of Maryland medical students (20 students), Pharmacogenomics, 4 hours of lecture and discussion, Summer 2015-2019

2017-2019 Small Group Discussion Leader

Cell and Molecular Biology, MSPR 513, University of Maryland medical students (20 students), Spring 2017-2019.

Grant Support

Active

9/19/18-8/31/20 (PI, 20%)

“A Community-Based Approach to Overcoming Barriers to Cascade Screening

for Long QT Syndrome”

NIH/NHGRI R21 HG010412

Annual Direct Costs: $137,500

Total Direct Costs: $275,000

7/1/2018 - 3/31/2023 (MPI, 20%)

“Genetics of Response to Canagliflozin”

NIH/NIDDK R01 DK118942

Annual Direct Costs: $441,860

Total Direct Costs: $2,209,302

01/15/16 – 3/31/19 (Co-Inv, 10%; PI – S. Taylor)

“Pharmacogenomics of GLP1 Receptor Agonists: Pilot Study Investigating Nonsynonymous Variants in Two Candidate Genes (GIPR and GCGR).”

American Diabetes Association 1-16-ICTS-112

Annual Direct Costs: $200,000

Total Direct Costs: $600,000

7/1/16-9/30/18, NCE (PI, 10%)

“Toward Precision Medicine of Diabetes Treatment: a pilot and feasibility study of DPP4 inhibitors.”

NIH/NIDDK via JHU Pilot & Feasibility Grant

Annual Direct Costs: $40,000

Total Direct Costs: $80,000

9/15/05 - 8/31/20* (Co-Inv, 10%; PI – B. Mitchell/S. Taylor) *from 7/1/18-9/31/20

“Mid-Atlantic Nutrition Obesity Research Center”

NIH/NIDDK P30 DK072488

Annual Direct Costs: $811,637

Total Direct Costs: $12,174,560

My role is to support visiting scientist program

5/01/18-4/30/19 (Co-Inv, 10%; PI – T.Pollin)

“Genomic Diagnosis and Individualized Therapy of Highly Penetrant Genetic Diabetes”

NIH/NHGRI U01 HG007775 (admin supplement)

Annual Direct Costs: $362,382

Total Direct Costs: $362,382

My role is to support pharmacogenetic implementation studies

9/1/19-8/31/20 (MPI, 5%)

Do Vitamin D supplements protect against adverse effect of canagliflozin on bone health?

NIH/NIDDK R01DK118942 (admin supplement)

Annual Direct Costs: $100,000

Total Direct Costs: $154,377

Completed

4/16/15-4/15/18 (Co-Inv, 10%; PI - S. Taylor)

“Pharmacogenetics of SGLT2 inhibitors: Pilot & Feasibility Project”

NIH/NIDDK R21 DK105401

Annual Direct Costs: $137,500

Total Direct Costs: $275,000

My role was to assist with the study design, conduct, and analysis

8/01/05-7/31/15 (Co-Inv, 20%; PI – J. Johnson)

“Pharmacogenomic Evaluation of Antihypertensive Responses”

NIH/NIGMS U01 GM074492

Annual Direct Costs: $977,365

Total Direct Costs: $9,773,655

My role was to lead the pharmacogenetics of adverse metabolic effects

9/23/05-8/30/17 (Co-Inv, 25%; PI – A. Shuldiner)

“Pharmacogenomics of Anti-platelet Intervention-2 Study (PAPI-2)”

NIH/NHLBI U01HL105198

Annual Direct Costs: $955,697

Total Direct Costs: $11,468,365

My role was to assist with study design, data analysis, and interpretation

9/30/14 – 09/29/16 (Co-Inv, 5%; PI – C. Overby)

“Electronic Health Record-linked Decision Support for Communicating Genomic

Data to Physicians”

NIH/AHRQ R21 KS

Annual Direct Costs: $137,500

Total Direct Costs: $275,000

My role was to support the development of CYP2C19 content for cardiologists

9/01/12-8/31/14 (PI, 10%)

“NELL1: A paracrine regulator of visceral obesity”

NIH/NIDDK via NORC

Pilot & Feasibility Grant

Annual Direct Costs: $30,000

Total Direct Costs: $60,000

09/01/08-07/31/13 (PI, 75%; Mentors – A. Shuldiner and S. Liggett)

“Uncoupling Protein Polymorphisms and Cardiometabolic Responses to (-

blockers”

NIH/NHLBI K23 HL091120

Annual Direct Costs: $122,654

Total Direct Costs: $613,268

07/01/06-06/30/08 (PI, 20%)

“Pathway Pharmacogenetics and Angiotensin Receptor Blocker Responses”

American Heart Association, Heartland Affiliate

Beginning Grant-in-Aid

Annual Direct Costs: $72,500

Total Direct Costs: $145,000

07/01/06-06/30/07 (PI, 8%)

“Uncoupling protein polymorphisms and acute coronary syndrome outcomes”

American College of Clinical Pharmacy

Frontiers Career Development Research Award

Annual Direct Costs: $28,269

Total Direct Costs: $28,269

2/22/05-12/31/09 (Co-Inv , 10%; PI – D. Kelly & M. Province)

SCCOR in Cardiac Dysfunction and Disease- Project 5 - Pharmacogenetics of

Post-ACS Therapy (Province)

NIH/NHLBI

P50 HL077113

Annual Direct Costs: $185,556

Total Direct Costs: $742,225

My role was to assist in the analysis/interpretation of pharmacogenetic studies

2/22/05-12/31/09 (Project PI, 50%)

SCCOR in Cardiac Dysfunction and Disease- Core B- Applied Genomics Core

NIH/NHLBI

Annual Direct Costs: $201,405

Total Direct Costs: $804,620

My role was to oversee the core which provided applied genomics support to the

SCCOR projects

1/1/02-12/31/06 (Postdoctoral Fellow, 50%; PI – J. Johnson)

“(-receptor polymorphisms and cardiovascular pharmacogenomics”

NIH/NHLBI

K24 HL68834-01

My role was in conducting the study and performing data analysis/interpretation

4/1/00-3/31/04 (Postdoctoral Fellow, 25%; PI – J. Johnson)

“(-adrenoceptor polymorphisms and hypertension”

NIH/NHLBI

R01 HL64691

My role was in data analysis and interpretation

7/1/2002-6/30/04 (Co-Inv, 25%; PI – J. Johnson)

“Heart disease outcomes: impact of genetics and pharmacogenetics”

Abbott Laboratories

My role as a fellow was sequencing CACNA1C gene and performing analyses

Publications

Peer-reviewed journal articles

1. Cavallari LH, Fashingbauer, LA, Beitelshees AL, Groo VL, Southworth MR, Viana MAG, Williams RE, Dunlap SH. Racial differences in patients' potassium concentrations during spironolactone therapy for heart failure. Pharmacotherapy 2004;24(6):750-756.

2. Zineh I, Beitelshees AL, Gaedigk A, Walker JR, Pauly DF, Eberst K, Leeder JS, Phillips MS, Gelfand CA, Johnson JA.  Pharmacokinetics and CYP2D6 genotypes do not predict metoprolol adverse events or efficacy in hypertension.  Clin Pharmacol Ther 2004;76(6):536-44.

3. Zineh I, Gerhard T, Aquilante CL, Beitelshees AL, Beasley BN, Hartzema AG. Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J 2004;4:354-8.

4. Zineh I, Pebanco GD, Aquilante CL, Gerhard T, Beitelshees AL, Beasley BN, Hartzema AG. Discordance between availability of pharmacogenetic studies and pharmacogenetics-based prescribing information for the top 200 drugs. Ann of Pharmacother 2006; 40(4):639-44.

5. Zineh I, Aquilante CL, Langaee TY, Beitelshees AL, Arrant CB, Wessel TR, Schofield RS. CXCL5 gene polymorphisms are related to systemic concentrations and leukocyte production of epithelial neutrophil-activating peptide (ENA-78). Cytokine 2006;33(5):258-63.

6. Aquilante CL, Zineh I, Beitelshees AL, Langaee TY. Common laboratory methods in pharmacogenomic studies. Am J Health Syst Pharm 2006;63(21):2101-10.

7. Beitelshees AL, Zineh I, Yarandi HN, Pauly DF, Johnson JA. Discordant (-blocker effects on clinic, ambulatory, resting, and exercise hemodynamics in patients with hypertension. Pharmacotherapy 2006;26(9):1247-54.

8. Beitelshees AL, Zineh I, Yarandi HN, Pauly DF, Johnson JA. Influence of phenotype and pharmacokinetics on (-blocker drug target pharmacogenetics. Pharmacogenomics J 2006;6(3):174-8.

9. Beitelshees AL, McLeod HL. Applying pharmacogenomics to enhance the use of biomarkers for drug effect and drug safety. (Invited review). Trends Pharmacol Sci 2006;27(9):498-502.

10. Lobmeyer MT, Gong Y, Terra SG, Beitelshees AL, Langaee TY, Pauly DF, Scofield RS, Hamilton KK, Patterson JH, Adams KF, Hill JA, Aranda JM, Johnson JA. Synergistic polymorphisms of the (1- and (2c-adrenergic receptors and the influence on left ventricular ejection fraction response to (-blocker therapy in heart failure. Pharmacoget Genom 2007; 17(4):277-82. PMID: 17496726

11. Zineh I, Beitelshees AL, Haller MJ. NOS3 Polymorphisms are Associated with Arterial Stiffness in Children with Type 1 Diabetes. Diabetes Care 2007;30: 689-693. PMID: 17327342

12. Aquilante CL, Beitelshees AL, Zineh I. Predictors of serum matrix metalloproteinase-8 (MMP-8) concentrations in nondiabetic subjects without cardiovascular disease. Clin Chim Acta 2007;379:48-52. PMID: 17254561

13. Gong Y, Beitelshees AL, Wessel J, Langaee TY, Schork NJ, Johnson JA. SNP discovery and haplotype analysis of BK channel (-1 subunit. Pharmacoget Genom 2007;17(4):267-75. PMID: 17496725

14. Beitelshees AL, Gong Y, Schork NJ, Cooper-DeHoff RM, Langaee TY, Shriver MD, Pepine CJ, Johnson JA. KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genom 2007;17(9):719-29. PMID: 17700361

15. Gerhard T, Gong Y, Beitelshees AL, Mao X, Lobmeyer MT, Cooper-DeHoff RM, Langaee TY, Schork NJ, Shriver MD, Pepine CJ, Johnson JA. Alpha-adducin polymorphism associated with increased risk of adverse cardiovascular outcomes: Results from INVEST-GENES. Am Heart J 2008; 156:397-404. PMID: 18657677

16. Beitelshees AL, Zineh I.  Renin-angiotensin-aldosterone system (RAAS) pharmacogenomics: implications in heart failure management.  Heart Failure Reviews 2010;May;15(3):209-17. PMID: 18351457.

17. Zineh I, Beitelshees AL, Welder GJ, Hou W, Nasser C, Wu J, Cresci S, Province MA, Spertus JA. Epithelial neutrophil-activating peptide (ENA-78), acute coronary syndrome prognosis, and modulatory effect of statins. PLoS ONE 2008;3(9)e3117. PMID: 18769620

18. Johnson JA, Boerwinkle E, Zineh I, Chapman AB, Bailey KR, Cooper-DeHoff RM, Gums JG, Curry RW, Gong Y, Beitelshees AL, Schwartz GL, Turner ST. Pharmacogenomics of Antihypertensive drugs: Rationale and Design of the Pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Am Heart J 2009;157(3):442-9. PMID: 19249413

19. Zineh I, Beitelshees AL, Silverstein JH, Haller MJ. Serum MCP-1 concentrations associate with diabetes status but not arterial stiffness in children with type 1 diabetes. Diabetes Care 2009;32(3):465-7. PMID: 19092169

20. Johnson JA, Gong Y, Bailey K, Cooper-DeHoff RM, Chapman AB, Turner ST, Schwartz GL, Campbell K, Schmidt S, Beitelshees AL, Boerwinkle E, Gums JG. Combination antihypertensive therapy with hydrochlorothiazide and atenolol: effect of initiation order. Clin Pharmacol Ther 2009;86:533-9. PMID: 19571804, PMCID: PMC2765524

21. Beitelshees AL, Navare H, Wang D, Gong Y, Wessel J, Moss JI, Langaee TY, Cooper-DeHoff RM, Sadee W, Pepine CJ, Schork NJ, Johnson JA. CACNA1C gene polymorphisms, cardiovascular disease outcomes and treatment response. Circ Cardiovasc Genet 2009;2:362-370. PMID: 20031608, PMCID: PMC2761685.

22. Aquilante CL, Beitelshees AL, Cavallari LH, Lee CR, Maciejewski S, Momary KM, Vardeny O, Zineh I. Key articles relative to cardiovascular pharmacogenomics. Pharmacotherapy 2009;29(9):1110–51.

23. Beitelshees AL, Gong Y, Bailey KR, Turner ST, Chapman AB, Schwartz GL, Gums JG, Boerwinkle E, Johnson JA. Comparison of office, ambulatory, and home blood pressure antihypertensive response to atenolol and hydrochlorthiazide. J Clin Hypertens (Greenwich) 2010;12(1):14-21. PMID: 20047624, PMCID: PMC2841560.

24. Cooper-DeHoff RM, Wen S, Beitelshees AL, Zineh I, Gums JG, Turner ST, Gong Y, Hall K, Parekh V, Chapman AB, Boerwinkle E, Johnson JA. Impact of abdominal obesity on incidence of adverse metabolic effects associated with antihypertensive medications. Hypertension 2010;55:61-68. PMID: 19917874, PMCID: PMC2811061

25. Beitelshees AL, Finck BN, Leone TC, Cresci S, Wu J, Province, MA, Fabbrini E, Kirk E, Zineh I, Klein S, Spertus JA, Kelly DP.  Interaction between the UCP2 -866 G>A polymorphism, diabetes, and beta-blocker use among patients with acute coronary syndromes.  Pharmacogenet Genomics 2010;20(4):231-8. PMID: 20145583, PMCID: PMC2842450.

26. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, Johnson JA, Bailey KR. Plasma renin activity predicts blood pressure responses to (-blocker and thiazide diuretic as monotherapy and add-on therapy for hypertension. Am J Hypertension 2010;23(9):1014-22. PMCID: PMC2941699

27. Cresci S, Huss JM, Beitelshees AL, Jones PG, Minton MR, Dorn GW, Kelly DP, McLeod HL. A PPARa promoter variant impairs ERR-dependent transactivation and decreases mortality after acute coronary ischemia in patients with diabetes. PLoS ONE 2010;5(9): e12584. doi:10.1371/journal.pone.0012584. PMCID: PMC2933242

28. Niu Y, Gong Y, Langaee TY, Davis HM, Elewa H, Beitelshees AL, Moss JI, Cooper-DeHoff RM, Pepine CJ, Johnson JA. Genetic variation in the beta 2 subunit of the voltage-gated calcium channel (CACNB2) and pharmacogenetic association with adverse cardiovascular outcomes in the International Verapamil SR- Trandolapril Study-Genetic Substudy (INVEST-GENES). Circ Cardiovasc Genet 2010;3:548-555. PMID: 21156931. PMC3060561.

29. Lobmeyer MT, Wang L, Zineh I, Turner ST, Gums JG, Chapman AB, Cooper-DeHoff RM, Beitelshees AL, Bailey KR, Boerwinkle EA, Pepine CJ, Johnson JA. Polymorphisms in genes coding for GRK2 and GRK5 and response differences in antihypertensive treated patients. Pharmacogenet Genomics 2011;21(1):42-9. PMID: 21127457. PMCID: PMC3028503.

30. Beitelshees AL, Johnson JA, Hames ML, Gong Y, Cooper-DeHoff RM, Wu J, Cresci S, Ma CX, Pepine CJ, Province MA, Spertus JA, McLeod HL. Aromatase gene polymorphisms are associated with survival among patients with cardiovascular disease in a sex-specific manner. PLoS ONE 2010; 5(12): e15180. doi:10.1371/journal.pone.0015180. PMID: 21170323. PMCID: PMC3000815.

31. Beitelshees AL, Horenstein RB, Vesely MR, Mehra MR, Shuldiner AR. Pharmacogenetics and clopidogrel response in patients undergoing percutaneous coronary interventions. (Invited review). Clin Pharmacol Ther 2011;89(3):455-9. PMID: 21270785.

32. Gong Y*, Beitelshees AL*, Cooper-DeHoff RM, Lobmeyer MT, Langaee TY, Wu J, Cresci S, Province MA, Spertus JA, Pepine CJ, Johnson JA. Chromosome 9p21 haplotypes and prognosis in Caucasian and African American patients with coronary artery disease. Circ Cardiovasc Genet 2011;4(2):169-78. PMID: 21372283. PMCID: PMC3101633. *Contributed equally

33. Beitelshees AL, Veenstra DL. Evolving research and stakeholder perspectives on pharmacogenomics. JAMA 2011;306(11):1252-3. PMID: 21934059.

34. Johnson JA, Cavallari LH, Beitelshees AL, Lewis JP, Shuldiner AR, Roden DM. Pharmacogenomics: application to the management of cardiovascular disease. Clin Pharmacol Ther 2011;90(4):519-31. PMID: 21918509.

35. Smith SM, Gong Y, Turner ST, Cooper-DeHoff RM, Beitelshees AL, Chapman AB, Boerwinkle E, Bailey K, Johnson JA, Gums JG. Blood pressure responses and metabolic effects of hydrochlorothiazide and atenolol. Am J Hypertens 2012; 25(3):359-65. PMCID: PMC3288583.

36. Reese ES, Mullins CD, Beitelshees AL, Onukwugha E. The cost-effectiveness of CYP2C19 genotype screening to select clopidogrel or prasugrel for antiplatelet therapy. Pharmacotherapy; 2012;32(4):323-32. PMID: 22461122. PMCID: PMC3883873.

37. Duarte JD, Turner ST, Tran B, Chapman AB, Bailey KR, Gong Y, Gums JG, Langaee TY, Beitelshees AL, Cooper-Dehoff RM, Boerwinkle E, Johnson JA. Association of chromosome 12 locus with antihypertensive response to hydrochlorothiazide may involve differential YEATS4 expression. Pharmacogenomics J. 2013;13(3):257-63. PMID: 22350108.

38. Duarte JD, Zineh I, Burkley B, Gong Y, Langaee TY, Turner ST, Chapman AB, Boerwinkle E, Gums JG, Cooper-DeHoff RM, Beitelshees AL, Bailey KR, Fillingim RB, Kone BC and Johnson JA. Effects of genetic variation in H3K79 methylation regulatory genes on clinical blood pressure and blood pressure response to hydrochlorothiazide. J Transl Med 2012;10(1):56. PMID: 22440088. PMCID: PMC3320544

39. Turner ST, Schwartz GL, Chapman AB, Beitelshees AL, Gums JG, Cooper-DeHoff RM, Boerwinkle E, Johnson JA, Bailey KR. Power to identify a genetic predictor of antihypertensive drug response using different methods to measure blood pressure response. J Transl Med 2012;10(1):47. PMID: 22413836.

40. Cresci S, Dorn GW, Jones PG, Beitelshees AL, Li AY, Lenzini PA, Province MA, Spertus JA, Lanfear DE. Adrenergic-pathway gene variants influence beta-blocker-related outcomes after acute coronary syndrome in a race-specific manner. J Am Coll Cardiol 2012; 4;60(10):898-907. PMID: 22703928

41. Karnes JH, McDonough CW, Gong Y, Vo TT, Langaee TY, Chapman AB, Gums JG, Beitelshees AL, Bailey KR, Del-Aguila J, Boerwinkle EA, Pepine CJ, Turner ST, Johnson JA, Cooper-DeHoff RM.  Association of KCNJ1 variation with change in fasting glucose and new onset diabetes during HCTZ treatment. Pharmacogenomics J. 2012. Aug 21. doi: 10.1038/tpj.2012.34. PMID: 22907731

42. Beitelshees AL, Aquilante CL, Allayee H, Langaee TY, Welder GJ, Schofield R, Zineh I. CXCL5 polymorphisms are associated with variable blood pressure in cardiovascular disease-free adults. Human Genomics 2012; 6:9. doi:10.1186/1479-7364-6-9

43. Vandell AG, Lobmeyer MT, Gawronski BE, Langaee TY, Gong Yan, Gums JG, Beitelshees AL, Turner ST, Chapman AB, Cooper-DeHoff RM, Bailey KR, Boerwinkle E, Pepine CJ, Liggett SB, Johnson JA. G protein receptor kinase 4 (GRK4) polymorphisms: Beta-blocker pharmacogenetics and treatment related outcomes in hypertension. Hypertension 2012;60(4):957-64.

44. McDonough CW, Burbage SE, Duarte JD, Gong Y, Langaee TY, Turner ST, Gums JG, Chapman AB, Bailey KR, Beitelshees AL, Boerwinkle E, Pepine CJ, Cooper-DeHoff RM, Johnson JA.  Association of variants in NEDD4L with blood pressure response and adverse cardiovascular outcomes in hypertensive patients treated with thiazide diuretics.  Journal of Hypertension 2013;31(4)698-704. PMID: 23353631

45. Gong Y, McDonough CW, Wang Z, Cooper-DeHoff RM, Langaee TY, Beitelshees AL, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Turner ST, Johnson JA. Hypertension susceptibility loci and blood pressure response to antihypertensives – results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Circ Cardiovasc Genet 2013; 5(6):686-91. PMID: 23087401. PMCID: PMC3529147.

46. Asselbergs FW, Guo Y, van Iperen EP, Sivapalaratnam S, Tragante V, Lanktree MB, Lange LA, Almoguera B, Appelman YE, Barnard J, Baumert J, Beitelshees AL, Bhangale TR, Chen YD, Gaunt TR, Gong Y, Hopewell JC, Johnson T, Kleber ME, Langaee TY, Li M, Li YR, Liu K, McDonough CW, et al. Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet 2012; 91(5):823-38. PMID: 23063622.

47. Guo Y, Lanktree MB, Taylor KC, Hakonsarson H, Lange LA, Keating BJ; The IBC 50K SNP array BMI Consortium. Gene-centric meta-analyses of 108,912 individuals confirm known body mass index loci and reveal three novel signals. Hum Mol Genet 2012; Jan 1;22(1):184-201. PMID: 23001569.

48. Del-Aguila JL, Beitelshees AL, Cooper-DeHoff RM, et al. Genome-wide association analyses suggest NELL1 influences adverse metabolic response to HCTZ in African- Americans. Pharmacogenomics J 2014;14:35-40; doi:10.1038/tpj.2013.3. PMID: 23400010. PMCID:

PMC3812324

49. Chapman AB, Cotsonis G, Parkeh V, Schwartz GL, Gong Y, Bailey KR, Turner ST, Gums JG, Beitelshees AL, Cooper-DeHoff R, Boerwinkle E, Johnson JA. Night blood pressure responses to atenolol and hydrochlorothiazide in black and white patients with essential hypertension. Am J Hypertens 2014;27(4):546-54. PMID: 23886594

50. Ganesh SK, Tragante V, Guo W, Guo Y, Lanktree MB, Smith EN, Johnson T, Castillo BA, Barnard J, Baumert J, Chang YP, Elbers CC, Farrall M, Fischer ME, Franceschini N, Gaunt TR, Gho JM, Gieger C, Gong Y, Isaacs A, Kleber ME, Leach IM, McDonough CW, Meijs MF, Mellander O, Molony CM, Nolte IM, Padmanabhan S, Price TS, Rajagopalan R, Shaffer J, Shah S, Shen H, Soranzo N, van der Most PJ, Van Iperen EP, van Setten J, Vonk JM, Zhang L, Beitelshees AL, Berenson GS, Bhatt DL, Boer JM, Boerwinkle E, Burkley B, Burt A, Chakravarti A, Chen W, Cooper-Dehoff RM, Curtis SP, Dreisbach A, Duggan D, Ehret GB, Fabsitz RR, Fornage M, Fox E, Furlong CE, Gansevoort RT, Hofker MH, Hovingh GK, Kirkland SA, Kottke-Marchant K, Kutlar A, Lacroix AZ, Langaee TY, Li YR, Lin H, Liu K, Maiwald S, Malik R; METASTROKE, Murugesan G, Newton-Cheh C, O'Connell JR, Onland-Moret NC, Ouwehand WH, Palmas W, Penninx BW, Pepine CJ, Pettinger M, Polak JF, Ramachandran VS, Ranchalis J, Redline S, Ridker PM, Rose LM, Scharnag H, Schork NJ, Shimbo D, Shuldiner AR, Srinivasan SR, Stolk RP, Taylor HA, Thorand B, Trip MD, van Duijn CM, Verschuren WM, Wijmenga C, Winkelmann BR, Wyatt S, Young JH, Boehm BO, Caulfield MJ, Chasman DI, Davidson KW, Doevendans PA, Fitzgerald GA, Gums JG, Hakonarson H, Hillege HL, Illig T, Jarvik GP, Johnson JA, Kastelein JJ, Koenig W; LifeLines Cohort Study, März W, Mitchell BD, Murray SS, Oldehinkel AJ, Rader DJ, Reilly MP, Reiner AP, Schadt EE, Silverstein RL, Snieder H, Stanton AV, Uitterlinden AG, van der Harst P, van der Schouw YT, Samani NJ, Johnson AD, Munroe PB, de Bakker PI, Zhu X, Levy D, Keating BJ, Asselbergs FW. Loci influencing blood pressure identified using a cardiovascular gene-centric array. Hum Mol Genet. 2013 Apr 15;22(8):1663-78. PMID: 23303523. PMCID: PMC3657476

51. Lewis JP, Ryan K, O'Connell JR, Horenstein RB, Damcott CM, Gibson Q, Pollin TI, Mitchell BD, Beitelshees AL, Pakzy R, Tanner K, Parsa A, Tantry US, Bliden KP, Post WS, Faraday N, Herzog W, Gong Y, Pepine CJ, Johnson JA, Gurbel PA, and Shuldiner AR. Genetic Variation in PEAR1 is Associated with Platelet Aggregation and Cardiovascular Outcomes. Circ Cardiovasc Genet 2013; 6(2):184-92. doi: 10.1161/CIRCGENETICS.111.964627. PMID: 23392654. PMCID: PMC3715320.

52. Wikoff WR, Frye RF, Zhu H, Gong Y, Boyle S, Churchill E, Cooper-Dehoff RM, Beitelshees AL, Chapman AB, Fiehn O, Johnson JA, Kaddurah-Daouk R; Pharmacometabolomics Research Network. Pharmacometabolomics reveals racial differences in response to atenolol treatment. PLoS One. 2013;8(3):e57639. doi: 10.1371/journal.pone.0057639. Epub 2013 Mar 11. PMID: 2353676650. PMCID: PMC3594230

53. Shuldiner AR, Relling MV, Peterson JF, Hicks JK, Freimuth RR, Sadee W, Pereira NL, Roden DM, Johnson JA, Klein TE; Pharmacogenomics Research Network Translational Pharmacogenetics Program Group, Shuldiner AR, Vesely M, Robinson SW, Ambulos N Jr, Stass SA, Kelemen MD, Brown LA, Pollin TI, Beitelshees AL, Zhao RY, Pakyz RE, Palmer K, Alestock T, O'Neill C, Maloney K, Branham A, Sewell D, Relling MV, Crews K, Hoffman J, Cross S, Haidar C, Baker D, Hicks JK, Bell G, Greeson F, Gaur A, Reiss U, Huettel A, Cheng C, Gajjar A, Pappo A, Howard S, Hudson M, Pui CH, Jeha S, Evans WE, Broeckel U, Altman RB, Gong L, Whirl-Carrillo M, Klein TE, Sadee W, Manickam K, Sweet KM, Embi PJ, Roden D, Peterson J, Denny J, Schildcrout J, Bowton E, Pulley J, Beller M, Mitchell J, Danciu I, Price L, Pereira NL, Weinshilboum R, Wang L, Johnson JA, Nelson D, Clare-Salzler M, Elsey A, Burkley B, Langaee T, Liu F, Nessl D, Dong HJ, Lesko L, Freimuth RR, Chute CG. The pharmacogenomics research network translational pharmacogenetics program: overcoming challenges of real-world implementation. Clin Pharmacol Ther 2013 Aug;94(2):207-10. PMID: 23588301. PMCID: PMC3720847.

54. Yerges-Armstrong LM, Ellero-Simatos S, Georgiades A, Zhu H, Lewis JP, Horenstein RB, Beitelshees AL, Dane A, Reijmers T, Hankemeier T, Fiehn O, Shuldiner AR, Kaddurah-Daouk R. Purine pathway implicated in mechanism of resistance to aspirin therapy: pharmacometabolomics-informed pharmacogenomics. Clin Pharmacol Ther 2013 Oct;94(4):525-32. PMID: 23839601

55. Gong Y, McDonough CW, Beitelshees AL, O’Connell JR, Karnes JH, Turner ST, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Johnson JA, Cooper-DeHoff RM. PROX1 gene variant is associated with glucose change after antihypertensive treatment. Pharmacotherapy 2014; Feb;34(2):123-30. PMID: 24122840.

56. Turner ST, Boerwinkle E, O'Connell JR, Bailey KR, Gong Y, Chapman AB, McDonough CW, Beitelshees AL, Schwartz GL, Gums JG, Padmanabhan S, Hiltunen TP, Citterio L, Donner KM, Hedner T, Lanzani C, Melander O, Saarela J, Ripatti S, Wahlstrand B, Manunta P, Kontula K, Dominiczak AF, Cooper-DeHoff RM, Johnson JA. Genomic association analysis of common variants influencing antihypertensive response to hydrochlorothiazide. Hypertension. 2013 Aug;62(2):391-7. PMID: 23753411. PMCID: PMC3780966

57. Vandell AG, McDonough CW, Gong Y, Langaee TY, Lucas AM, Chapman AB, Gums JG, Beitelshees AL, Bailey KR, Johnson RJ, Boerwinkle E, Turner ST, Cooper-DeHoff RM, Johnson JA.  Hydrochlorothiazide-induced hyperuricemia in the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. J Intern Med 2014;276(5):486-97. PMID: 24612202

58. Yoneyama S, Guo Y, Lanktree MB, Barnes MR, Elbers CC, Karczewski KJ, Padmanabhan S, Bauer F, Baumert J, Beitelshees A, Berenson GS, Boer JM, Burke G, Cade B, Chen W, Cooper-Dehoff RM, Gaunt TR, Gieger C, Gong Y, Gorski M, Heard-Costa N, Johnson T, Lamonte MJ, McDonough C, Monda KL, Onland-Moret NC, Nelson CP, O'Connell JR, Ordovas J, Peter I, Peters A, Shaffer J, Shen H, Smith E, Speilotes L, Thomas F, Thorand B, Verschuren WM, Anand SS, Dominiczak A, Davidson KW, Hegele RA, Heid I, Hofker MH, Huggins GS, Illig T, Johnson JA, Kirkland S; the Look AHEAD Research Group, König W, Langaee TY, McCaffery J, Melander O, Mitchell BD, Munroe P, Murray SS, Papanicolaou G, Redline S, Reilly M, Samani NJ, Schork NJ, van der Schouw YT, Shimbo D, Shuldiner AR, Tobin MD, Wijmenga C, Yusuf S; the GIANT Consortium; the CARe IBC Consortium, Hakonarson H, Lange LA, Demerath EW, Fox CS, North KE, Reiner AP, Keating B, Taylor KC. Gene-centric meta-analyses for central adiposity traits in up to 57,412 individuals of European descent confirm known loci and reveal several novel associations.  Hum Mol Genet. 2014;23(9):2498-510. PMID: 24345515.

59. Cooper-DeHoff RM, Hou W, Weng L, Baillie RA, Beitelshees AL, Gong Y, Shahin MH, Turner ST, Chapman A, Gums JG, Boyle SH, Zhu H, Wikoff WR, Boerwinkle E, Fiehn O, Frye RF, Kaddurah-Daouk R, Johnson J. A. Is a Diabetes-Linked Amino Acid Signature Associated with Beta Blocker-Induced Impaired Fasting Glucose? Circ Cardiovasc Genetics. 2014 Apr 1;7(2):199-205. PMID: 24627569

60. Shuldiner AR, Palmer K, Pakyz RE, Alestock TD, Maloney KA, O'Neill C, Bhatty S, Schub J, Overby CL, Horenstein RB, Pollin TI, Kelemen MD, Beitelshees AL, Robinson SW, Blitzer MG, McArdle PF, Brown L, Jeng LJB, Zhao RY, Ambulos N, Vesely MR. 2014. Implementation of pharmacogenetics: The University of Maryland personalized anti-platelet pharmacogenetics program. Am J Med Genet C Semin Med Genet. 2014; 166C:76–84. PMID: 24616408. PMCID: PMC4066997.

61. Ellero-Simatos S, Lewis JP, Georgiades A, Yerges-Armstrong LM, Beitelshees AL, Horenstein RB, Dane A, Harms AC, Ramaker R, Vreeken RJ, Perry CG, Zhu H, Sànchez CL, Kuhn C, Ortel TL, Shuldiner AR, Hankemeier T, Kaddurah-Daouk R. Pharmacometabolomics reveals that serotonin is implicated in aspirin response variability. CPT Pharmacometrics Syst Pharmacol. 2014 Jul 16;3:e125. doi: 10.1038/psp.2014.22. PMID: 25029353. PMCID: PMC4120016.

62. Moore MJ, Gong Y, Hou W, Hall K, Schmidt SO, Curry RW, Beitelshees AL, Chapman AB, Turner ST, Schwartz GL, Bailey K, Boerwinkle E, Gums JG, Cooper-DeHoff RM, Johnson JA. Predictors for glucose change in hypertensive participants following short-term treatment with atenolol or hydrochlorothiazide. Pharmacotherapy 2014 Nov;34(11):1132-40. Doi:10.1002/phar.1483. [Epub ahead of print]. PMID: 25202885.

63. Del-Aguila JL, Cooper-DeHoff RM, Chapman AB, Gums JG, Beitelshees AL, Bailey K, Turner ST, Johnson JA, Boerwinkle E. Transethnic meta-analysis suggests genetic variation in the HEME pathway influences potassium response in patients treated with hydrochlorthiazide. Pharmacogenomics J 2015 Apr;15(2):153-7. PMID: 25201287. PMCID: PMC4362777.

64. Weng L, Quinlivan E, Gong Y, Beitelshees AL, Shahin MH, Turner S Chapman A, Gums J, Johnson JA, Frye RF, Garrett TJ and Cooper-DeHoff RM. Association of branched and aromatic amino acid levels with metabolic syndrome and impaired fasting glucose in hypertensive patients. Metabolic Syndrome and Related Disorders 2015;13(5):195-202. PMID: 25664967.

65. Washam JB, Herzog CA, Beitelshees AL, Cohen MG, Henry TD, Kapur NK, Mega JL, Menon V, Page RL 2nd, Newby LK; on behalf of the American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology, Council on Cardiovascular Surgery and Anesthesia, Council on Functional Genomics and Translational Biology, Council on the Kidney in Cardiovascular Disease, and Council on Quality of Care and Outcomes Research. Pharmacotherapy in chronic kidney disease patients presenting with acute coronary syndrome: a scientific statement from the American Heart Association. Circulation 2015;131 (12):1123-49. PMID: 25712269

66. Cutting EM, Overby CL, Banchero M, Pollin T, Kelemen M, Shuldiner AR, Beitelshees AL. Using workflow modeling to identify areas to improve genetic test processes in the University of Maryland translational pharmacogenomics project. AMIA Annu Symp Proc 2015; Nov 5;2015:466-74. PMID: 26958179. PMCID: PMC4765659.

67. Beitelshees AL, Voora D, Lewis JP. Personalized antiplatelet and anticoagulant therapy: applications and significance of pharmacogenomics. Pharmgenomics Pers Med 2015 Feb 9;8:43-61. PMID: 25897256. PMCID: PMC4397717.

68. Ellero-Simatos*, Beitelshees AL*, Lewis JP, Yerges-Armstrong, Georgiades A, Dane A, Harms AC, Strassburg K, Guled F, Hendriks MM, Horenstein RB, Shuldiner AR, Hankemeier T, Kaddurah-Daouk R. Oxylipid profile of low-dose aspirin exposure: a pharmacometabolomics study. J Am Heart Assoc 2015;Oct 26;4(10). PMID: 26504148. *Contributed equally

69. Gong Y, McDonough CW, Beitelshees AL, Rouby NE, Hiltunen TP, O’Connel JR, Padmanabhan S, Langaee TY, Hall K, Schmidt SO, Curry RW, Gums JG, Donner KM, Kontula KK, Bailey KR, Boerwinkle E, Takahashi A, Tanaka T, Kubo M, Chapman AB, Turner ST, Pepine CJ, Cooper-DeHoff RM, Johnson JA. PTPRD gene associated with blood pressure response to atenolol and resistant hypertension. J Hypertens 2015 Nov;33(11):2278-85. PMID: 26425837.

70. Gong Y, Wang Z, Beitelshees AL, McDonough CW, Langaee TY, Hall K, Schmidt SO, Curry RW, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Pharmacogenomic genome-wide meta-analysis of blood pressure response to beta-blockers in hypertensive African Americans. Hypertension 2016;67:556-63.

PMID: 26729753

71. Rotroff DM, Shahin MH, Gurley SB, Zhu H, Motsinger-Reif A, Beitelshees AL, Fiehn O, Johnson JA, Elbadawi-Sidhu M, Frye RF, Gong Y, Weng L, Cooper-DeHoff RM, Kaddurah-Daouk R. Pharmacometabolomic assessments of atenolol and hydrochlorothiazide treatment reveal novel drug response phenotypes. CPT Pharmacometrics Syst Pharmacol 2015;4(11):669-79. PMID: 26783503.

72. Vu A, Kosmiski LA, Beitelshees AL, Prigeon R, Sidhom MS, Bredbeck B, Predhomme J, Deininger KM, Aquilante CL. Pharmacodynamic effects of low-dose pioglitazone in patients with metabolic syndrome without diabetes mellitus. Pharmacotherapy 2016;36:252-62. PMID: 26822630

73. Perry CG, Maloney KA, Beitelshees AL, Jeng LJ, Ambulos NP Jr, Shuldiner AR, Blitzer MG. Educational innovations in clinical pharmacogenomics. Clin Pharmacol Ther 2016;99:582-4. PMID: 26875057

74. Chang SW, Gong Y, McDonough CW, Langaee TY, Nasiri Kenari N, Beitelshees AL, Gums JG, Chapman AB, Turner ST, Johnson JA, Cooper-DeHoff RM. Melatonin pathway and atenolol-related glucose dysregulation: is there a correlation? Clin Transl Sci 2016;9:114-22. PMID: 26946962

75. Shahin MH, Gong Y, McDonough CW, Rotroff DM, Beitelshees AL, Garrett TJ, Gums JG, Motsinger-Reif A, Chapman AB, Turner ST, Boerwinkle E, Frye RF, Fiehn O, Cooper-DeHoff RM, Kaddurah-Daouk R, Johnson JA. A genetic response score for hydrochlorothiazide use: insights from genomics and metabolomics. Hypertension 2016;68:621-9. PMID: 27381900

76. De Oliverira FA, Shahin MH, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Boerwinkle E, Turner ST, Frye RF, Fiehn O, Kaddurah-Daouk R, Johnson JA, Cooper-DeHoff RM. Novel plasma biomarker of atenolol-induced hyperglycemia identified through a metabolomics-genomics integrative approach. Metabolomics 2016;12(8)pii:129. PMID: 28217400.

77. Cutting E, Banchero M, Beitelshees AL, Cimino JJ, Fiol GD, Gurses AP, Hoffman MA, Jeng LJ, Kawamoto K, Kelemen M, Pincus HA, Shuldiner AR, Williams MS, Pollin TI, Overby CL. User-centered design of multi-gene sequencing panel reports for clinicians. J Biomed Inform 2016;S1532-0464(16)30068-5. PMID: 27423699

78. Cavallari LH, Beitelshees AL, Blake KV, Dressler LG, Duarte JD, Elsey A, Eichmeyer JN, Empey PE, Franciosi JP, Hicks JK, Holmes AM, Jeng L, Lee CR, Lima JJ, Limdi NA, Modlin J, Obeng AO, Petry N, Pratt VM, Skaar TC, Tuteja S, Voora D, Wagner M, Weitzel KW, Wilke RA, Peterson JF, Johnson JA. The IGNITE pharmacogenetics working group: An opportunity for building evidence with pharmacogenetic implementation in a real-world setting. Clin Trans Sci 2017;10(3):143-6.  PMID: 28294551

79. Weng L, Gong Y, Culver J, Gardell SJ, Petucci C, Morse AM, Frye RF, Turner ST, Chapman A, Boerwinkle E, Gums J, Beitelshees AL, Borum PR, Johnson JA, Garrett TJ, McIntyre LM, Cooper-DeHoff RM. Presence of arachidonoyl-carnitine is associated with adverse cardiometabolic responses in hypertensive patients treated with atenolol. Metabolomics 2016;12(10)pii:160. PMID: 28217400.

80. Mehanna M, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Schwartz GL, Johnson JA, Turner ST, Cooper-DeHoff.RM. Blood pressure response to metoprolol and chlorthalidone in hypertensive European and African Americans. J Clin Hypertens 2017;19(12):1301-1308.

81. Magvanjav O, Gong Y, McDonough CW, Chapman AB, Turner ST, Gums JG, Bailey KR, Boerwinkle E, Beitelshees AL, Tanaka T, Kubo M, Pepine CJ, Cooper-DeHoff RM, Johnson JA. Genetic variants associated with uncontrolled blood pressure on combination therapy with a thiazide diuretic/beta-blocker in the PEAR and INVEST trials. J Am Heart Assoc. 2017;6(11):e006522.

82. Cavallari LH, Lee CR, Beitelshees AL, Cooper-DeHoff RM, Duarte JD, Voora D, Kimmel SE, McDonough CW, Gong Y, Dave CV, Pratt VM, Alestock TD, Anderson RD, Alsip J, Ardati AK, Brott BC, Brown L, Chumnumwat S, …. Shuldiner AR, Winterstein AG, Johnson JA; IGNITE Network. Multisite investigation of outcomes with implementation of CYP2C19 genotype-guided antiplatelet therapy after percutaneous coronary intervention. JACC Cardiovasc Interv 2018;Jan 22;11(2):181-191. doi: 10.1016/j.jcin.2017.07.022

83. Sa ACC, Webb A, Gong Y, McDonough CW, Datta S, Langaee TY, Turner ST, Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, Johnson JA. Whole transcriptome sequencing analyses reveal molecular markers of blood pressure response to thiazide diuretics. Sci Rep 2017;7(1):16068.

84. Empey PE, Stevenson JM, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshees AL, Coons JC, Duarte JD, Franchi F, Jeng LJB, Johnson JA, Kreutz RP, Limdi NA, Maloney KA, Owusu Obeng A, Peterson JF, Petry N, Pratt VM, Rolini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, Cavallari LH, Lee CR; IGNITE Network. Multisite investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy. Clin Pharmacol Ther 2018;104(4):664-74.

85. Shahin MH, Gong Y, Frye RF, Rotroff DM, Beitelshees AL, Baillie RA, Chapman AB, Gums JG, Turner ST, Boerwinkle E, Motsinger-Reif A, Fiehn O, Cooper-DeHoff RM, Han X, Kaddurah-Daouk R, Johnson JA. Sphingolipid metabolomics pathway impacts thiazide diuretcis blood pressure response: insights from genomics, metabolomics, and lipidomics. J Am Heart Assoc 2017; Dec 29;7(1). pii:e006656.

86. Shahin MH, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshees AL, Boerwinkle E, Gums JG, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome-wide association approach identified novel genetic predictors of heart rate response to β-blockers. J Am Heart Assoc 2018; Feb 24;7(5). pii:e006463.

87. Singh S, McDonough CW, Gong Y, Alghamdi WA, Arwood MJ, Bargal SA, Dumeny L, Li WY, Mehanna M, Stockard B, Yang G, de Oliveira FA, Fredette NC, Shahin MH, Bailey KR, Beitelshees AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome wide association study identifies the HMGCS2 locus to be associated with chlorthalidone induced glucose increase in hypertensive patients. J Am Heart Assoc 2018 Mar 9;7(6). pii:e007339.

88. Sa ACC, Webb A, Gong Y, McDonough CW, Shahin MH, Datta S, Langaee TY, Turner ST, Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer SE, Cooper-DeHoff RM, Sadee W, Johnson JA. Blood pressure signature genes and blood pressure response to thiazide diuretics: results from the PEAR and PEAR-2 studies. BMC Med Genomics 2018;11(1):55. PMID: 29925376.

89. Zekavat SM, Ruotsalainen S, Handsaker RE, Alver M, Bloom J, Poterba T, Seed C, Ernst J, Chaffin M, Engreitz J, ……Kathiresan S, Natarajan P; NHLBI TOPMed Lipids Working Group. Deep coverage whole genome sequences and plasma lipoprotein(a) in individuals of European and African ancestries. Nat Commun 2018;9(1):2606. PMID:29973585.

90. Natarajan P, Peloso GM, Zekavat SM, Montasser M, Ganna A, Chaffin M, Khera AV, Zhou W, Bloom JM, Engreitz JM, Ernst J, O’Connell JR…Kathiresan S; NHLBI TOPMed Lipids Working Group. Nat Commun 2018;9(1):3391. PMID:3014000.

91. Singh S, Wang Z, Shahin MH, Langaee TY, Gong Y, Turner ST, Chapman AB, Gums JG, McDonough CM, Bailey KR, Beitelshees AL, Cooper-DeHoff RM, Scherer SE, Boerwinkle E, Johnson JA. Targeted sequencing identifies missense variant in the BEST3 gene associated with anti-hypertensive response to hydrochlorothiazide. Pharmacogenetics and Genomics. 2018;28(11):251-55. PMID: 30289819.

92. He KY, Li X, Kelly TN, Liang J, Cade BE, Assimes TL, Becker LC, Beitelshees AL, Bress AP, Chang YC, Chen YI, de Vries PS, Fox ER, Franceschini N, Furniss A, Gao Y, Haessler J, Hwang SJ, Irvin MR< Kalyani RR, Liu CT, Liu C, Martin LW, Montasser ME, Muntner PM, Mwasongwe S, Palmas W, Reiner AP, Shimbo D, Smith JA, Snively BM, Yanek LR, Boerwinkle E, Correa A, Cupples LA, He J, Karda SLR, Kooperberg C, Mathias RA, Mitchell BD, Psaty BM, Vasan RS, Rao DC, Rich SS, Rotter JI, Wilson JG, NHLBI Trans-Omics for Precision Medicine (TOPMed) Consortium, TOPMed Blood Pressure Working Group, Chakravarti A, Morrison AC, Levy D, Arnett DK, Redline S, Zhu X. Leveraging linkage evidence to identify low-frequency and rare variants on 16p13 associated with blood pressure using TOPMed whole genome sequencing data. Hum Genet 2019 Feb;138(2):199-210. PMID: 30671673.

93. Mehanna M, Wang Z, Gong Y, McDonough CW, Beitelshees AL, Gums JG, Chapman AB, Schwartz GL, Bailey KR, Johnson JA, Turner ST, Cooper-DeHoff RM. Plasma renin activity is a predictive biomarker of blood pressure response in European but not in African Americans with uncomplicated hypertension. Am J Hypertens 2019 Feb 9 [Epub ahead of print]. PMID: 30753254.

94. Solayman MH, Langaee TY, Gong Y, Shahin MH, Turner ST, Chapman AB, Gums JG, Boerwinkle E, Beitelshees AL, El-Hamamsy M, El-Wakeel L, Cooper-DeHoff, Badary OA, Johnson JA. Effect of plasma microRNA on antihypertensive response to beta-blockers in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) studies. Eur J Pharm Sci 2019; Apr 1;131:93-98.PMID: 30753892.

95. Cavallari LH, Van Driest SL, Prows CA, Bishop JR, Limdi NA, Pratt VM, Ramsey LB, Smith DM, Tuteja S, Duong BQ, Hicks JK, Lee JC, Obeng AO, Beitelshees AL, Bell GC, Blake K, Croana DJ, Dressler L, Gregg RA, Hines LJ, Scott SA, Shelton RC, Weitzel KW, Johnson JA, Peterson JF, Empey PE, Skaar TC; IGNITE Network. Multi-site investigation of strategies for the clinical implementation of CYP2D6 genotyping to guide drug prescribing. Genet Med 2019; Mar 21 [Epub ahead of print].PMID: 30894703.

Non-peer reviewed journal articles

1. Beitelshees AL, Humma LM, DiDomenico RJ. What’s best in the cath lab? Today in Cardiology 2003;6(1):18.

2. Beitelshees AL. ACC/AHA guidelines for treatment of STEMI updated. Today in Cardiology 2004;7(10):8-10.

Book Chapters

1. Beitelshees AL, Zineh I. Pharmacogenomics and Laboratory Tests. In Lee M (ed), Basic Skills in Interpreting Laboratory Data. Bethesda, MD: American Society of Health-System Pharmacists. 2009:565-576.

2. Beitelshees AL, Charlab R. Pharmacogenomics and Molecular Testing. In Lee M (ed), Basic Skills in Interpreting Laboratory Data, Bethesda, MD: American Society of Health-System Pharmacists. 2013:161-173.

3. Beitelshees AL, Charlab R. Pharmacogenomics and Molecular Testing. In Lee M (ed), Basic Skills in Interpreting Laboratory Data, Bethesda, MD: American Society of Health-System Pharmacists. 2017:135-148.

Abstracts and/or Proceedings

1. Humma LM, Fashingbauer LA, Beitelshees AL, Just VL, Southworth MR, Williams RE, Dunlap S. Effects of race and gender on potassium requirements with spironolactone therapy in heart failure. J Cardiac Failure 2002;8(4):S60 (P218).

2. Beitelshees AL, Bauman JL, Southworth MR, DiDomenico RJ, Dunlap SH, Fashingbauer LA, Humma LM. Cost-savings associated with a decreased need for potassium supplementation in heart failure patients started on spironolactone. Pharmacotherapy 2002;22:1327. Presented as platform presentation at American College of Clinical Pharmacy 2002 Annual Meeting. Albuquerque, NM. October 21, 2002.

3. Beitelshees AL, Zineh I, Yarandi HN, Puckett BJ, Pauly DF, Johnson  JA. Contribution of Gs( and (2-adrenergic receptor polymorphisms to antihypertensive response to (-blockers. Clin Pharmacol Ther 2003;73(2):P98. Abstract.  Presented as a moderated poster at the 104th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Washington, D.C., April 2003.

4. Beitelshees AL, Zineh I, Yarandi HN, Puckett BJ, Langaee TY, Pauly DF, Johnson JA. Utility of clinic versus ambulatory blood pressure for pharmacogenetic studies. Pharmacotherapy 2003;23(10):1357. Finalist Best Student, Resident, Fellow Paper Award. Presented as poster at the American College of Clinical Pharmacy 2003 Annual Meeting, Atlanta, GA, November 2003.

5. Beitelshees AL, Cavallari LH, Gaston KG, Okorochukwu TU, Johnson JA. Beta1-adrenergic receptor polymorphisms and hypertension. Clin Pharmacol Ther 2004;75(2):P61. Presented as poster presentation at the 105th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Miami, FL, April 2004.

6. Beitelshees AL, Zineh I, Gaedigk A, Leeder JS, Walker JR, Eberst K, Timmerbeil BS, Lobmeyer M, Pauly DF, Johnson JA. Effect of CYP2D6 phenotype and metoprolol pharmacokinetics on adverse effects. Clin Pharmacol Ther 2004;75(2):P95. Presented as moderated poster presentation at the 105th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Miami, FL, April 2004.

7. Beitelshees AL, Langaee TY, Johnson JA. SNP discovery using denaturing HPLC for the CACNA1C gene. Pharmacotherapy 2004;124(10):1458. Runner-up, Best Student, Resident, Fellow Paper Award Competition. Presented as platform presentation at the ACCP 2004 Annual Meeting, Dallas, TX, October 2004.

8. Zineh I, Gerhard T, Aquilante CL, Beitelshees AL, Beasley BN, Hartzema AG. Availability of pharmacogenomics-based prescribing information in drug package inserts for currently approved drugs. Pharmacogenomics J 2004;4:354-8. Presented at the 20th International Conference on Pharmacoepidemiology and Therapeutic Risk Management of the International Society for Pharmacoepidemiology, Bordeaux, France, August 2004.

9. Gong Y, Beitelshees AL, Stauffer L, Gaston K, Sloan A, Yarandi HN, Langaee TY, Cooper-Dehoff RM, Pepine CJ. (2-adrenergic receptor (B2AR) polymorphisms and antihypertensive response to (-blocker therapy in the INVEST trial. Clin Pharmacol Ther 2005;77(2):P97. Presented as a poster presentation at the American Society for Clinical Pharmacology and Therapeutics 106th Annual Meeting, Orlando, FL, March 2005.

10. Beitelshees AL, Gong Y, Moss J, Cooper-Dehoff RM, Pepine CJ, Johnson JA. Variable blood pressure response to verapamil by KCNMB1 genotype. Clin Pharmacol Ther 2005;77(2):P97. Presented as oral presentation at the American Society for Clinical Pharmacology and Therapeutics 106th Annual Meeting, Orlando, FL, March 2005.

11. Gerhard T, Gong Y, Beitelshees AL, Lobmeyer M, Schiefelbein L, Langaee TY, Cooper-DeHoff RM, Johnson JA. Association between CV outcomes, diuretic use and the alpha-adducin gene; Results from the INternational VErapamil SR-Trandolapril STudy (INVEST). Circulation 2005; 112 (17): U670-U670 Suppl. S.

12. Aquilante CL, Beitelshees AL, Rome LC, Kosmiski L. Influence of resistin promoter polymorphisms on plasma resistin levels in nondiabetic subjects. Pharmacotherapy 2006; 26: number 87. Presented as poster at the American College of Clinical Pharmacy 2006 Spring Practice and Research Forum. Monterey, CA. April 2006.

13. Gong Y, Beitelshees AL, Stauffer LA, Langaee TY, Cooper-DeHoff RM, Pepine CJ, Johnson JA, 2006. Beta adrenergic receptors polymorphisms are associated with response to beta-blocker therapy in the INternal VErapamil SR-Trandolapril Sudy (INVEST). Clin Pharmacol Ther 2006;79(2):P30. Presented as podium presentation at the 107th Annual meeting of the American Society for Clinical Pharmacology and Therapeutics in Baltimore, MD, March 2006.

14. Beitelshees AL, Gong Y, Cooper-DeHoff RM, Burt L, Stauffer L, Pepine CJ, Johnson JA. KCNMB1 genotype associated with cardiovascular outcomes in the INternational VErapamil SR/trandolapril STudy (INVEST). Clin Pharmacol Ther 2006;79(2):P41. Presented as poster presentation at the American Society for Clinical Pharmacology and Therapeutics 107th Annual Meeting. Baltimore, MD. March 2006.

15. Cresci S, Huss JM, Beitelshees AL, Jones PG, Minton MR, Spertus JA, McLeod HL. Mortality in Diabetic Acute Coronary Syndrome Patients is Associated with a Novel Variant in the PPAR alpha Gene Promoter that Confers Differential ERR Binding [3190]. Circulation 2006. Presented as an oral presentation at the American Heart Association Scientific Sessions 2006, Chicago, IL. November 2006.

16. Lanfear D, Jones PG, Marsh S, Beitelshees AL, Cresci S, McLeod HL, Spertus JA. Genetic Polymorphisms in the ACE Gene and the GJA4 Gene Modify ACE-inhibitor Efficacy in Post-ACS Patients [3691]. Circulation 2006. Presented as an oral presentation at the American Heart Association Scientific Sessions 2006, Chicago, IL. November 2006.

17. Beitelshees AL, Cresci S, Jones P, Minton MR, Kelly DP, Spertus J, McLeod HL. UCP2 genotype influences response to post-acute coronary syndrome therapy [3690]. Circulation 2006:114(18):II-788. Presented as an oral presentation at the American Heart Association Scientific Sessions 2006, Chicago, IL. November 2006.

18. Welder GJ, Beitelshees AL, Aquilante CL, Allayee H, Langaee TY, Schofield RS, Zineh I. Influence of CXCL5 polymorphisms on blood pressure in adults without cardiovascular disease. Poster presentation at the Cold Spring Harbor Laboratory Pharmacogenomics Meeting, Cold Spring Harbor, NY. November 2006.

19. Price ET, Beitelshees AL, Zineh I. Liver-X receptor-( (LXRA) haplotype and C-reactive protein response to atorvastatin. Clin Pharmacol Ther 2007;81(Suppl 1):S34. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, March 21-24, 2007, Anaheim, CA.

20. Zineh I, Beitelshees AL, Haller MJ.  Association between NOS3 polymorphisms and arterial stiffness in children with type 1 diabetes.  Clin Pharmacol Ther 2007;81(Suppl 1):S15.  Poster presentation at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) Annual Meeting, March 21-24, 2007, Anaheim, CA.

21. Ma CX, Cresci S, Wu J, Minton M, Jones PG, Province MA, McLeod HL, Spertus JA, Beitelshees AL. Aromatase Genotype Predicts Survival After Acute Coronary Syndrome. Clin Pharmacol Ther 2007;81(Suppl 1):S11. Oral presentation at the American Society of Clinical Pharmacology and Therapeutics (ASCPT) 2007 Annual Meeting, March 21-24, 2007, Anaheim, CA.

22. Zineh I, Welder GJ, Beitelshees AL, Chegini N, Wu J, Cresci S, Province MA, Spertus JA.  CXCL5 is an endothelial target and pharmacogenetic candidate for statins [289].  J Clin Lipidol 2007;1(5):449.  Presented at the Drugs Affecting Lipid Metabolism (DALM) Meeting, October 4-7, 2007, New York, NY.

23. Beitelshees AL, Xiao L, Cresci S, Jones PG, Wu J, Minton MR, Province MA, Kelly DP, McLeod HL, Spertus JA. UCP2 -866 G/A polymorphism influences beta-blocker response in post-acute coronary syndrome diabetic individuals [373]. Pharmacotherapy 2007;348. Presented at the American College of Clinical Pharmacy 2007 Annual Meeting, October 14-17, 2007, Denver, CO.

24. Baker J, Xiao L, Lanfear DE, Cresci S, Jones PG, Wu J, Province MA, Spertus JA, Beitelshees AL. Interaction between ADRA2C genotype and beta-blocker response in acute coronary syndromes [363]. Pharmacotherapy 2007;348. Presented at the American College of Clinical Pharmacy 2007 Annual Meeting in Denver, CO October 14-17.

25. Welder GJ, Beitelshees AL, Aquilante CL, Allayee H, Langaee TY, Schofield RS, Zineh I. CXCL5 polymorphisms are associated with variable blood pressure in cardiovascular disease-Free adults [2533]. Circulation 2007; 116: II_559. Presented as an oral presentation at the 2007 Scientific Sessions, Orlando, FL.

26. Beitelshees AL, Zineh I, Cresci S, Wu J, Minton MR, Province MA, Spertus JA. CXCL5 genotype is associated with mortality after acute coronary syndromes [2321]. Circulation 2007; 116: II_507. Presented as an oral presentation at the 2007 Scientific Sessions, Orlando, FL.

27. Navare HA, Beitelshees AL, Gong Y, Langaee TY, Cooper-Dehoff, RM, Pepine CJ, Johnson JA. CACNA1C polymorphisms and cardiovascular outcomes in the international verapamil SR/trandolapril study-genetic substudy (INVEST-GENES). Clin Pharmacol Ther 2008;83(Suppl 1):S4. Presented as a poster as the American Society of Clinical Pharmacology and Therapeutics (ASCPT) 2008 Annual Meeting, April 2-5, 2008, Orlando, FL.

28. Beitelshees AL, Welder GJ, Hames ML, Zineh I. Influence of ramipril on nitric oxide pathway genes in endothelial cells. Clin Pharmacol Ther 2008;83(Suppl 1):S47. Presented as poster at the American Society of Clinical Pharmacology and Therapeutics (ASCPT) 2008 Annual Meeting, April 2-5, 2008, Orlando, FL.

29. Beitelshees AL, Welder GJ, Zineh I. Effect of ramipril on basal production of endothelium-derived growth factors. Clin Pharmacol Ther 2008;83(Suppl 1):S47. Presented as poster at the American Society of Clinical Pharmacology and Therapeutics (ASCPT) 2008 Annual Meeting, April 2-5, 2008, Orlando, FL.

30. Beitelshees AL, Zineh I, Cresci S, Wu J, Minton MR, Province MA, Spertus JA. Interaction between NOS3 -786 T>C genotype and ACE Inhibitor therapy in acute coronary syndromes. Clin Pharmacol Ther 2008;83(Suppl 1):S8. Presented as oral presentation at the American Society of Clinical Pharmacology and Therapeutics (ASCPT) 2008 Annual Meeting, April 2-5, 2008, Orlando, FL.

31. Beitelshees AL, Pacanowski MA, Frye RF, Zineh I.  Influence of UCP2 -866G>A polymorphism on coenzyme Q10 (CoQ10) concentrations.  Clin Chem Lab Med 2008;46(8):A124.  Poster presentation at the 4th Biologie Perspective Santorini Conference, September 16-19, 2008, Santorini, Greece.

32. Robertson WF, Beitelshees AL, Zineh I, Lobmeyer MT, Shin J, Pauly DF, Johnson JA. CXCL5/ENA-78 genotype and progression to death or transplantation in heart failure patients. Clin Pharmacol Ther 2009;85(Suppl 1):S5. Oral presentation at the American Society of Clinical Pharmacology and Therapeutics (ASCPT) 2009 Annual Meeting, March 18-21, 2009, Washington, DC.

33. Hames ML, Welder GJ, Wittmann J, Cooper-DeHoff RM, Pepine CJ, Johnson JA, Beitelshees AL. Aromatase genotype in the INternational VErapamil SR/trandolapril Study (INVEST). Pharmacotherapy 2009;29:272e. Presented as a poster at the 2009 American College of Clinical Pharmacy Annual Meeting, October 18-21, 2009.

34. Moore MJ, Chik VPW, Gong Y, Langaee TY, Chapman AB, Schwartz GL, Turner ST, Gums JG, Cooper-DeHoff RM, Beitelshees AL, Johnson JA. Association between melatonin receptor 1B single nucleotide polymorphisms (SNPs) and response to antihypertensive drugs. Clin Pharmacol Ther. 2010;87(1):S45. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics 111th Annual Meeting, Atlanta, GA, March 2010.

35. Vandell AG, Lobmeyer MT, Gawronski B, Langaee TY, Gong Y, Beitelshees AL, Gums JG, Turner ST, Chapman AB, Cooper-DeHoff RM, Liggett SB, Johnson JA. Influence of G protein receptor kinase 4 (GRK4) polymorphisms on blood pressure response to the ß–blocker atenolol. Clin Pharmacol Ther 2011; 89(S1):S74. Presented at the American Society for Clinical Pharmacology and Therapeutics 112th Annual Meeting, Dallas, TX, March 2011.

36. Karnes JH, Vo TT, Gong Y, Langaee TY, Beitelshees AL, Turner ST, Chapman AB, Gums JG, Bailey K, Boerwinkle E, Pepine CJ, Johnson JA, Cooper-DeHoff RM. KCNJ1 SNPs are associated with increased fasting glucose and risk of new onset diabetes during HCTZ therapy.  Clin Pharmacol Ther 2011;89(S1):S46. Presented at the American Society for Clinical Pharmacology and Therapeutics 112th Annual Meeting, Dallas, TX, March 2011.

37. Gong Y, McDonough CW, Wang Z, Cooper-DeHoff RM, Langaee TY, Beitelshees AL, Turner ST, Chapman AB, Gums JG, Bailey KR, Boerwinkle E, Johnson JA. Hypertension susceptibility loci and blood pressure response to antihypertensives – results from the pharmacogenomic evaluation of antihypertensive responses (PEAR) study. Clin Pharmacol Ther 2012; 91 (S1): S16. Presented at the American Society for Clinical Pharmacology and Therapeutics 113th Annual Meeting, National Harbor, MD, March 14-17, 2012.

38. Moore MJ, Gong Y, Hou W, Chapman AB, Langaee TY, Schwartz GL, Turner ST, Gums JG, Bailey K, Boerwinkle E, Beitelshees AL, Cooper-DeHoff RM, Johnson JA. Clinical Predictors of Dysglycemic Effects Associated with Use of Beta Blockers and Thiazide Diuretics. Clin Pharmacol Ther. 2012;91(1):S24-25. Presented at the American Society for Clinical Pharmacology and Therapeutics 113th Annual Meeting, National Harbor, MD, March 14-17, 2012.

39. Vandell AG, McDonough CW, Langaee TY, Burkley B, Gong Y, Turner ST, Gums JG, Chapman AB, Beitelshees AL, Cooper-DeHoff RM, Johnson JA.  Association of FTO with Hydrochlorothiazide (HCTZ)-induced elevation in uric acid (UA) in African American (AA) hypertensives in the Pharmacogenomic Evaluation of Antihypertensive Response (PEAR) study. Clin Pharmacol Ther 2012; 91 (S1): S59. Presented at the American Society for Clinical Pharmacology and Therapeutics 113th Annual Meeting, National Harbor, MD, March 14-17, 2012.

40. Gong Y, McDonough CW, Wang Z, Langaee TY, Beitelshees AL, Gums JG, Bailey KR, Boerwinkle E, Chapman AB, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome-wide Association Analysis (GWAS) of Blood Pressure Response to Atenolol-Results from Pharmacogenomic Evaluation of Antihypertensive Responses Study. Clin Pharmacol Ther 2014; 95 (S1): S16. Oral presentation at American Society for Clinical Pharmacology and Therapeutics Annual meeting on March 20, 2014 Atlanta, GA.

41. Shahin MM, Gong Y, Langaee T, Beitelshees AL, Rotroff DM, Chapman AB, Gums JG, Turner ST, Motsinger-Reif A, Frye RF, Fiehn O, Johnson JA, Cooper-DeHoff R, Han X, Kaddurah-Daouk R. Metabolomics, genomics and lipidomics reveal novel signatures of hydrochlorothiazide response in pharmacogenomic evaluation of antihypertensive responses (Pear) study. Clin Pharmacol Ther 2015;97:S30. doi:10.1002/cpt.50. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting March 5-8, 2015 New Orleans, LA.

42. Shahin MH, Rotroff DM, Gong Y, Langaee T, McDonough CW, Beitelshees AL, Garrett TJ, Chapman AB, Gums JG, Turner ST, Motsinger-Reif A, Frye RF, Scherer SE, Sadee W, Fiehn O, Cooper-DeHoff RM, Kaddurah-Daouk R, Johnson JA. Integrating metabolomics and genomics reveals novel biomarkers of hydrochlorothiazide response in pharmacogenomic evaluation of antihypertensive responses (Pear) Study. Clin Pharmacol Ther 2015;97:S103. doi:10.1002/cpt.56. Awarded a Presidential Trainee Award. Presented as oral presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting March 5-8, 2015 New Orleans, LA.

43. Chang S, Gong G, McDonough CW, Nasiri Kenari N, Langaee T, Beitelshees AL, Gums JG, Chapman AB, Turner ST, Johnson JA, Cooper-DeHoff RM. Correlating the melatonin (MT) pathway with atenolol associated glucose dysregulation in the pharmacogenomics evaluation of antihypertensive responses (PEAR) study. Clin Pharmacol Ther 2015;97:S17. doi:10.1002/cpt.48 Awarded a Presidential Trainee Award. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting March 5-8, 2015 New Orleans, LA.

44. Ellero-Simatos S, Beitelshees AL, Lewis JP, Yerges-Armstrong LM, Georgiades A, Dane A, Harms AC, Strassburg K, Guled F, Hendriks MM, Horenstein RB, Shuldiner AR, Hankemeier T, Kaddurah-Daouk R. Oxylipid profile of low-dose aspirin exposure: a pharmacometabolomics study. Clin Pharmacol Ther 2015;97:S22. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting March 5-8, 2015 New Orleans, LA.

45. Rotroff D, Yerges-Armstrong L, Lewis J, Beitelshees A, Horenstein R, Shuldiner A, Motsinger-Reif A, Kaddurah-Daouk. Genome-wide association analysis with amine metabolites reveals novel loci impacting human metabolomics profiles. Clin Pharmacol Ther 2015;97:S61. Poster presentation at the American Society for Clinical Pharmacology and Therapeutics Annual Meeting March 5-8, 2015 New Orleans, LA.

46. Shahin MH, Sa AC, Webb A, Gong Y, Langaee TY, McDonough CW, Riva A, Beitelshees AL, Chapman AB, Gums JG, Turner ST, Frye RF, Scherer SE, Sadee W, Cooper-DeHoff RM, Johnson JA. Finding a Needle in the Haystack for Thiazide Diuretic Response Using Genomics/Transcriptomics in the Pharmacogenomic Evaluation of Antihypertenive Responses (Pear) Study. Clinical Pharmacology & Therapeutics 2016, 99: S19.

47. Sa AC, Webb A, Gong Y, McDonough CW, Shahin MH, Langaee TY, Turner ST, A. L. Beitelshees AL, Chapman AB, Boerwinkle E, Gums JG, Scherer S, Cooper-DeHoff RM, Sadee, Johnson JA. Hypertension (HTN)/Blood Pressure (BP) Signature Genes and BP Response to Thiazide Diuretics (TD): Results From Pear and Pear-2 Studies. Clinical Pharmacology & Therapeutics 2016, 99: S19 (PT23).

48. Cavallari LH, Denny JC, Lee CR, Beitelshees AL, Duarte JD, Kimmel SE, Voora D, McDonough CW, Gong Y, Wei WQ, Pratt VM, Chumnumwat S, Coons JC, Cooper-DeHoff RM, Dave CV, Dillon C, Hamadeh IS, Hines L, Howell LA, Jeng LJ, Lee YM, Skaar TC, Sriramoju VB, Stevenson JM, Vesely MR, Wake D, Kreutz RP, Stouffer GA, Wilke RA, Empey PE, Limdi NA, Roden DM, Shuldiner AR, Johnson JA, Peterson JF. Prospective Clinical Implementation of CYP2C19-Genotype Guided Antiplatelet Therapy After PCI: a Multi-Site Investigation of MACE Outcomes in a Real-World Setting. Circulation 2016;134:e711-712 (abstract #21050). Presented as a Late-Breaking Clinical Science Special Report: Precision Medicine on the Front Lines at the American Heart Association’s Scientific Sessions 2016. New Orleans, LA. November 15, 2016.

49. Shahin MH, Michailidis G, Gong Y, Beitelshees AL, Chapman AB, Gums JG, Boerwinkle E, Turner ST, Cooper-DeHoff RM, Johnson JA. Thiazide-Induced Hyperuricemia: Novel Insights from Metabolomics and Genomics Integration in the Pharmacogenomic Evaluation of Antihypertensive Responses 2 (PEAR2) Study. Clinical Pharmacology & Therapeutics 2017; 101: S13. (PT-028)

50. Singh S, Alghamdi W, Arwood MJ, Bargal SA, de Oliveira F, Dumeny L, Wen-Yi L, Mehanna M, Stockard B, Yang G, Fredette N, Shahin M, Bailey KR, Beitelshees AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Gong Y, McDonough CW, Cooper-DeHoff RM, Johnson JA. A Genome Wide Association Study to Identify Pharmacogenomic Variants Associated with Chlorthalidone Induced Glucose Change in African Americans. American Society for Clinical Pharmacology and Therapeutics. Clinical Pharmacology & Therapeutics 2017; 101:S9. (PT-019).

51. Singh S, Gong Y, McDonough CW, Bailey KR, Beitelshees AL, Boerwinkle E, Chapman AB, Gums JG, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome wide association study identifies novel pharmacogenetic variants associated with clhlorthalidone blood pressure response in African Americans (2018), American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther., 103: S50. doi:10.1002/cpt.993 (PI-139)

52. Singh S, Wang Z, Shahin MH, Langaee TY, Gong Y, McDonough CW, Bailey KR, Turner ST, Chapman A, Gums JG, Beitelshees AL, Cooper-DeHoff RM, Scherer S, Boerwinkle E, Johnson JA. Targeted sequencing identifies missense variant in the BEST3 gene associated with antihypertensive response to thiazide diuretics (2018), American Society for Clinical Pharmacology and Therapeutics. Clin. Pharmacol. Ther., 103: S5. doi:10.1002/cpt.993 (PT-001)

53. Shahin MH, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshees AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Cooper-DeHoff RM, Johnson JA. Genome-wide meta-analyses reveal novel predictors of heart rate response to β-blockers in the Pharmacogenetic Evaluation of Antihypertensive Responses (PEAR) studies. Clinical Pharmacology & Therapeutics 2018; 103: S15. (PI-001)

54. Shahin MH, Conrado DJ, Gonzalez D, Gong Y, Lobmeyer MT, Beitelshees AL, Boerwinkle E, Gums JG, Chapman A, Turner ST, Cooper-DeHoff RM, Johnson JA. β2-adrenergic receptor gene affects the negative chronotropic effects of β-blockers in the PEAR and PEAR2 studies. Clinical Pharmacology & Therapeutics 2018; 103: S15. (PI-002)

55. Empey PE, Stevenson JM, Tuteja S, Weitzel KW, Angiolillo DJ, Beitelshees AL, Coons JC, Duarte JD, Franchi F, Jeng LJB, Johnson JA, Kreutz RP, Limdi NA, Maloney KA, Owusu Obeng A, Peterson JF, Petry N, Pratt VM, Rollini F, Scott SA, Skaar TC, Vesely MR, Stouffer GA, Wilke RA, Cavallari LH, Lee CR; for the NHGRI Implementing GeNomics In PracTicE (IGNITE) Network. Multi-site investigation of strategies for the implementation of CYP2C19 genotype-guided antiplatelet therapy. Clin Pharmacol Ther. 2018: 103(Supplement 1), S31 (Abstract PI-066).

56. Shahin MH, Gong Y, Singh S, Beitelshees AL, Chapman AB, Gums JG, Boerwinkle E, Turner ST, Cooper-DeHoff RM, Garrett TJ, Johnson JA. Machine learning uncovers novel biomarkers of antihypertensive response in the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) Study. Clin Pharmacol Ther 2019;105:S27 (PT-013).

57. Singh S, Warren HR, Hiltunen E, Salvi E, ElRouby N, Garofalidou T, Fyhrquist F, Kontula KK, Glorioso V, Zaninello R, Glorioso N, Pepine CJ, Munroe PB, Beitelshees AL, Turner ST, Chapman AB, Boerwinkle E, Johnson JA, Gong Y, Cooper-DeHOff RM. Genome wide meta-analysis of blood pressure response to beta-blockers: results from international consortium of antihypertensive pharmacogenomics studies. Clin Pharmacol Ther 2019;105(S1):S27(PT-014).

Other Brief Communications

1. Johnson JA, Zineh I, Langaee TY, Beitelshees AL. “Caution with (1-adrenergic receptor genotyping - Reply". [letter] Clin Pharmacol Ther 2004;76:186.

2. Gerhard T, Beitelshees AL, Johnson JA. Re: Meckley LM, Veenstra DL. Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genom 2006; 16:139-147. [letter] Pharmacogenet Genomics 2006 Aug;16(8):613.

3. Beitelshees AL, McLeod HL. Clopidogrel Pharmacogenetics: Promising steps towards patient care? [Ediorial] Arterioscl Throm Vasc 2006;26:1681-1683.

4. Zineh I, Beitelshees AL, van Schaik RHN. Comment on the SACGHS`s report "Realizing the Promise of Pharmacogenomics: Opportunities and Challenges"

5. Beitelshees AL. Is ticagrelor the anti-platelet panacea? (Invited editorial). Circ Cardiovasc Genet 2010;3(6):489-91. PMID: 21079054. PMCID: PMC3052795.

6. Beitelshees AL. Personalized anti-platelet therapy: A RAPID-ly moving target. (Invited commentary). Lancet 2012;379:1680-2. PMID: 22464341.

Major Invited Speeches

Local:

1. Utility of Clinic Versus Ambulatory Blood Pressure for Pharmacogenetic Studies. ACPE approved seminar, University of Florida College of Pharmacy, Ken Finger Memorial Golf Classic October 2003.

2. Verapamil Pharmacogenetics. ACPE approved seminar, University of Florida Center for Pharmacogenomics seminar series, April 2004.

3. Antihypertensive pharmacogenomics: a focus on genotype-phenotype relationships. ACPE approved seminar, University of Florida Center for Pharmacogenomics seminar series, February 2005.

4. Heart failure therapeutics in the genomic era. CME approved seminar, Plenary Address, Congestive Heart Failure Update, Washington University School of Medicine. December 3, 2005.

5. Heart failure therapeutics in the genomic era. CME approved seminar, Missouri Baptist Medical Center Grand Rounds. February 8, 2006.

6. Optimizing cardiovascular therapeutics: from genotype to phenotype and back. CME approved seminar. Washington University Center for Cardiovascular Research Seminar Series. April 11, 2006.

7. Genome-Wide Association Studies in Cardiovascular Disease: Searching for a Needle in a Haystack? CME approved seminar, Cardiology Grand Rounds, University of Florida. March 20, 2008.

8. Hypertension Pharmacogenomics: Beyond Blood Pressure. Clinical Research Grand Rounds at the Welch Center, Johns Hopkins University, Baltimore, MD. October 6, 2010.

9. Pharmacogenomic Applications in Cardiovascular Diseases. Office of Clinical Pharmacology, Food and Drug Administration, Silver Spring, MD. March 10, 2010.

10. Precision Medicine in Cardiovascular Disease and Diabetes: From early stages to implementation. University of Maryland School of Pharmacy Pharmaceutical Sciences Department Seminar Series. May 11, 2016.

11. Pharmacogenomic Implementation at the University of Maryland. Seminar at Inova Health System Center for Personalized Health. September 23, 2016.

12. Clinical Pharmacogenomics: Applications to Patient Care. Washington Metropolitan Soceity of Health-System Pharmacists Spring Meeting. May 19, 2018.

13. Diabetes Pharmacogenetics- Present and Future. University of Maryland Endocrinology, Diabetes and Nutrition Grand Rounds. June 28, 2018.

National:

14. The influence of pharmacogenomics on health disparity and pain management. ACPE approved seminar, Pain and Palliative Care PRN Focus Session, 2006 American College of Clinical Pharmacy Annual Meeting, St. Louis, MO. October 26, 2006.

15. Integration of genomics into therapy selection. ACPE approved seminar, American Society of Health-System Pharmacists Midyear Meeting, Anaheim, CA. December 6, 2006.

16. The Basics of Pharmacogenomics. ACPE approved seminar, American College of Clinical Pharmacy Spring Meeting, Phoenix, AZ. April 7, 2008.

17. Beta-Blocker Pharmacogenetics: Hypertension and Heart Failure. CME approved Plenary Session, American Heart Association Scientific Sessions, Orlando, FL. November 16, 2009.

18. Using Pharmacogenetics in Pre-Emptive/Preventative Therapy: Ready for Primetime? American College of Clinical Pharmacy Spring Meeting, Charlotte, NC. April 24, 2010.

19. Genomics and Pharmacogenomics: Platelet Reactivity, Antiplatelet Drugs and Warfarin. American Heart Association Scientific Sessions, Chicago, IL. November 15, 2010. Session moderator.

20. Translating Genomic Discovery to Human Trials and Clinical Practice. American Heart Association Scientific Sessions, Los Angeles, CA. November 4, 2012. Session moderator.

21. Cardiovascular Genetics. Clinical Genomics, Scientific and Regulatory Aspects. United States Food & Drug Administration, White Oak Campus, MD. October 30, 2013.

22. Pharmacogenetics: Following the continuum of discovery to implementation. Seminar at University of Colorado School of Pharmacy. February 23, 2017.

23. Not Just One Gene: Medications affected by variability in multiple genes. 2017 UF Precision Medicine Conference. Invited speaker. March 9, 2017.

24. Pharmacogenetics. 78th Scientific Sessions American Diabetes Association. Invited speaker. June 24, 2018.

................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download